Mineralys Accounts Payable from 2010 to 2025
| MLYS Stock | 10.27 0.09 0.87% |
Accounts Payable | First Reported 2010-12-31 | Previous Quarter 691.1 K | Current Value 1 M | Quarterly Volatility 356.1 K |
Check Mineralys Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mineralys Therapeutics,'s main balance sheet or income statement drivers, such as Net Interest Income of 12.5 M, Depreciation And Amortization of 143.6 K or Interest Expense of 2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.22. Mineralys financial statements analysis is a perfect complement when working with Mineralys Therapeutics, Valuation or Volatility modules.
Mineralys | Accounts Payable |
Latest Mineralys Therapeutics,'s Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Mineralys Therapeutics, Common over the last few years. An accounting item on the balance sheet that represents Mineralys Therapeutics, obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Mineralys Therapeutics, are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Mineralys Therapeutics,'s Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mineralys Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
| Accounts Payable | 10 Years Trend |
|
Accounts Payable |
| Timeline |
Mineralys Accounts Payable Regression Statistics
| Arithmetic Mean | 676,634 | |
| Geometric Mean | 627,196 | |
| Coefficient Of Variation | 52.64 | |
| Mean Deviation | 212,452 | |
| Median | 529,000 | |
| Standard Deviation | 356,150 | |
| Sample Variance | 126.8B | |
| Range | 1.4M | |
| R-Value | 0.49 | |
| Mean Square Error | 103.9B | |
| R-Squared | 0.24 | |
| Significance | 0.06 | |
| Slope | 36,294 | |
| Total Sum of Squares | 1.9T |
Mineralys Accounts Payable History
About Mineralys Therapeutics, Financial Statements
Mineralys Therapeutics, shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although Mineralys Therapeutics, investors may analyze each financial statement separately, they are all interrelated. The changes in Mineralys Therapeutics,'s assets and liabilities, for example, are also reflected in the revenues and expenses on on Mineralys Therapeutics,'s income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Accounts Payable | 691.1 K | 1 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.